CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 20, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago ...
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Promising new Ionis-owned therapies advancing into the clinic include ION283 for Lafora disease, ION373 for a form of leukodystrophy and ION716 for prion diseases. "It's been a privilege to see Ionis' ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical ...
"In the third quarter of 2025, we delivered strong revenue performance, highlighted by TRYNGOLZA’s nearly 70% increase over the prior quarter. As a result of this strength and our fourth quarter ...
CARLSBAD, Calif., Sept. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Phase 3 Balance study of olezarsen in people with familial ...
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify ...
“Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no ...
“The approval of TRYNGOLZA marks an historic advance for people who have long struggled to control their dangerously high triglycerides, providing the only approved therapy for sHTG to dramatically ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 26, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Sep. 9, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results